ADC Therapeutics SA

Equities

ADCT

CH0499880968

Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 04:00:02 2024-04-26 pm EDT			5-day change	1st Jan Change
4.34 ^USD	-2.25%		-8.05%	+161.45%

Apr. 09	Transcript : ADC Therapeutics SA - Special Call
Apr. 04	Sector Update: Health Care Stocks Slump Late Afternoon	MT

ADC Therapeutics SA Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023

August 08, 2023 at 07:07 am EDT

ADC Therapeutics SA reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported revenue was USD 19.28 million compared to USD 17.29 million a year ago. Net loss was USD 47.12 million compared to USD 64.37 million a year ago. Basic loss per share from continuing operations was USD 0.58 compared to USD 0.84 a year ago.
For the six months, revenue was USD 38.28 million compared to USD 63.79 million a year ago. Net loss was USD 106.54 million compared to USD 81.04 million a year ago. Basic loss per share from continuing operations was USD 1.31 compared to USD 1.05 a year ago.

Latest news about ADC Therapeutics SA

Transcript : ADC Therapeutics SA - Special Call	Apr. 09
Sector Update: Health Care Stocks Slump Late Afternoon	Apr. 04	MT
ADC Therapeutics Shares Rise After Completion of Dose Escalation Part of Phase 1b Lymphoma Trial	Apr. 04	MT
Chiome Bioscience Cancels License Agreements with ADC Therapeutics	Mar. 31	MT
Guggenheim Initiates ADC Therapeutics With Buy Rating, $11 Price Target	Mar. 28	MT
Transcript : ADC Therapeutics SA, Q4 2023 Earnings Call, Mar 13, 2024	Mar. 13
ADC Therapeutics SA Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 13	CI
ADC Therapeutics SA Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 13	CI
RBC Lifts Price Target on ADC Therapeutics to $8 From $6, 'Encouraged' by Competitive Positioning; Outperform, Speculative Risk Kept	Feb. 26	MT
HC Wainwright Raises Price Target on ADC Therapeutics to $9 From $3, Maintains Buy Rating	Feb. 20	MT
Certain Common Shares of ADC Therapeutics SA are subject to a Lock-Up Agreement Ending on 3-FEB-2024.	Feb. 02	CI
Certain Restricted Stock Units of ADC Therapeutics SA are subject to a Lock-Up Agreement Ending on 3-FEB-2024.	Feb. 02	CI
Certain Warrants of ADC Therapeutics SA are subject to a Lock-Up Agreement Ending on 3-FEB-2024.	Feb. 02	CI
Certain Options of ADC Therapeutics SA are subject to a Lock-Up Agreement Ending on 3-FEB-2024.	Feb. 02	CI
ADC Therapeutics SA Enters First Amendment to the Loan Agreement	Jan. 19	CI
ADC Therapeutics Regains Compliance With NYSE Continued Listing Standards	Jan. 04	MT
HC Wainwright Adjusts Price Target on ADC Therapeutics to $3 From $12, Keeps Buy Rating	Nov. 20	MT
TD Cowen Downgrades ADC Therapeutics to Market Perform From Outperform	Nov. 09	MT
RBC Cuts Price Target on ADC Therapeutics to $6 From $7, Keeps Outperform, Speculative Risk	Nov. 08	MT
Transcript : ADC Therapeutics SA, Q3 2023 Earnings Call, Nov 07, 2023	Nov. 07
ADC Therapeutics SA Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
RBC Trims Price Target on ADC Therapeutics to $8 From $9 Amid Guidance Withdrawal, Keeps Outperform, Speculative Risk	23-09-12	MT
Transcript : ADC Therapeutics SA Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-11-2023 02:15 PM	23-09-11
ADC Therapeutics SA Announces Updates on ZYNLONTA® LOTIS Clinical Trial Programs At the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023)	23-08-30	CI
JPMorgan Upgrades ADC Therapeutics to Neutral From Underweight	23-08-10	MT

Chart ADC Therapeutics SA

Duration

Period

More charts

Company Profile

ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkinâs lymphoma and B-cell leukemia. It serves customers in the United States, Switzerland, and the United Kingdom.

Sector

Biotechnology & Medical Research

Calendar

2024-05-06 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for ADC Therapeutics SA

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.34 USD

Average target price

10.2 USD

Spread / Average Target

+135.02%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ADC THERAPEUTICS SA	+161.45%	359M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.73B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs